33,700
-0.15%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dong-A ST Co
Its shares trade on KRX under the ticker 170900.KS. It has been listed since 8 April 2013. In the fiscal year to 31 December 2025, it reported revenue of ₩808.78bn and a net loss of ₩28.59bn. At that date it held total assets of ₩1.41trn and shareholders' equity of ₩642.71bn.
Dong-A ST Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-04-08. The firm is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. The company produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The firm distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Apr 2013
- Website
- donga-st.com ↗
Leadership
Pay as last reported
- Mr. Jae Hun JungCo-President, Chief Executive Officer, Director, since 2024
- Mr. Jae Hong ParkCo-President, Director, since 2022
- Mr. Min Yeong KimCo-President, since 2021
- Mr. Seong Geun LeeManaging Director
- Mr. Ju Seop LeeManaging Director
- Mr. Yu Seok ShinManaging Director
- Mr. Sun Jong SohManaging Director
- Mr. Hyeong Heon KimAssistant Managing Director
- Mr. Hui Beom ParkAssistant Managing Director
- Mr. Ho Jun YangAssistant Managing Director
- Mr. Seung Min YangAssistant Managing Director
- Dae Wu LeeDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Dong-A ST Co Ltd possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong brand reputation built over the years, which fosters customer trust and loyalty. Secondly, Dong-A ST Co Ltd has a diverse portfolio of high-quality products, allowing it to cater to various customer needs. Thirdly, the company has a robust distribution network, enabling efficient product delivery and widespread market reach.
Weaknesses
- Despite its strengths, Dong-A ST Co Ltd also faces certain weaknesses that may hinder its performance. One major weakness is its limited international presence, which restricts its access to global markets and potential opportunities. Moreover, the company heavily relies on a few key customers, making it vulnerable to their potential shifts in demand or business decisions. Additionally, Dong-A ST Co Ltd might face challenges in adapting to rapidly changing market trends and technological advancements.
Opportunities
- There are several opportunities that Dong-A ST Co Ltd can capitalize on to enhance its growth and profitability. Firstly, the increasing demand for healthcare products and services in emerging markets presents a significant opportunity for expansion. Secondly, the company can explore partnerships and collaborations with other industry players, fostering innovation and accessing new customer segments. Furthermore, the rising trend of e-commerce provides a platform for Dong-A ST Co Ltd to expand its online presence and reach a wider customer base.
Threats
- Dong-A ST Co Ltd operates in a competitive market, facing several threats that may impact its business. One major threat is the presence of strong competitors with established market positions and larger resources. Additionally, regulatory changes and compliance requirements in the pharmaceutical industry can pose challenges to the company's operations. Furthermore, economic fluctuations and currency exchange rate fluctuations may have adverse effects on Dong-A ST Co Ltd's profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.